To print: Select File and then Print from your browser's menu --------------------------------------------------------------------------------------- Title: Monurol for Uncomplicated Urinary Tract Infection Cleared by FDA URL: http://www.pslgroup.com/dg/EF1E.htm Doctor's Guide December 19, 1996
NEW YORK, Dec. 19, 1996 -- Forest Laboratories, Inc. (AMEX: FRX), an international pharmaceutical manufacturer and marketer, announced today that Monurol(TM) (fosfomycin tromethamine) has been approved for marketing by the U.S. Food and Drug Administration (FDA). Monurol is the first one-time, one-dose antibiotic for uncomplicated urinary tract infection, as well as the first product of a new class of antibiotics. The approval of Monurol represents a unique option for the treatment of uncomplicated urinary tract infection, and the first new treatment for cystitis in nearly three years. Available in Europe since 1988, Monurol has been used to treat more than 11 million uncomplicated urinary tract infections in Germany, Italy, France, Spain and other countries. Forest Laboratories expects to launch Monurol to the U.S. market in April 1997. Uncomplicated urinary tract infections are one of the most common infections seen by primary care physicians. If left untreated, they can cause more serious infection and damage to the kidneys. Uncomplicated urinary tract infections are estimated to cause more than 7 million lost work days each year. Except for the historical information contained herein, the matters contained in this release are forward-looking statements that involve a number of risks and uncertainties, including the acceptance of new products, the impact of competitive products and pricing, the timely development and launch of new products, and the risk factors listed from time to time in the Company's SEC reports. --------------------------------------------------------------------------------------------- Copyright © 1999 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content. --------------------------------------------------------------------------------------------- This news story was printed from *Doctor's Guide to the Internet* located at http://www.docguide.com --------------------------------------------------------------------------------------- Return to News Story Page This site is maintained by webmaster@pslgroup.com Please contact us with any comments, problems or bugs. All contents Copyright (c) 1998 P\S\L Consulting Group Inc. All rights reserved.